NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.
复制标题
DOI：
10.1016/j.bbmt.2010.05.005
复制
发表时间：
2010-08
影响因子：
4.3
通讯作者：
Riddell, Stan
中科院分区：
文献类型：
--
作者：
Alyea, Edwin P.;DeAngelo, Daniel J.;Moldrem, Jeffrey;Pagel, John M.;Przepiorka, Donna;Sadelin, Michel;Young, James W.;Giralt, Sergio;Bishop, Michael;Riddell, Stan
关键词：
预防异基因造血干细胞移植后复发是最有可能提高恶性血液病患者存活率的方法。在这里，我们回顾了目前可用的移植疗法的局限性，以及正在开发的克服治疗耐药性或填补目前尚不存在的治疗方式的创新策略。这些新的策略包括非免疫学治疗，如靶向准备方案和移植后药物治疗，以及免疫干预，包括移植工程、供者淋巴细胞输注、T细胞工程、疫苗接种和基于树突状细胞的方法。恶性细胞的生物学以及宿主的几个方面已经被发现，即使是这些新的策略也无法成功。为了最大限度地提高成功的可能性，我们建议开展研究，开发更多的靶向治疗，用于准备方案或作为移植后的维持治疗，更好地表征移植物抗宿主病和移植物抗白血病/肿瘤效应中涉及的T细胞和树突状细胞亚群，确定免疫或非免疫治疗的时机策略以消除非周期癌症干细胞，确定更多免疫治疗的靶点，开发不受人类白细胞抗原限制的新疫苗，并开发识别复发高危人群的方法，以加快临床开发，避免对没有复发风险的患者的毒性。
Prevention of relapse after allogeneic hematopoietic stem cell transplantation is the most likely approach to improve survival of patients treated for hematologic malignancies. Herein we review the limits of currently available transplant therapies and the innovative strategies being developed to overcome resistance to therapy or to fill therapeutic modalities not currently available. These novel strategies include nonimmunologic therapies, such as targeted preparative regimens and posttransplant drug therapy, as well as immunologic interventions, including graft engineering, donor lymphocyte infusions, T cell engineering, vaccination and dendritic cell-based approaches. Several aspects of the biology of the malignant cells as well as the host have been identified that obviate success of even these newer strategies. To maximize the potential for success, we recommend pursuing research to develop additional targeted therapies to be used in the preparative regimen or as maintenance post-transplant, better characterize the T-cell and dendritic cells subsets involved in graft-versus-host disease and the graft-versus-leukemia/tumor effect, identify strategies for timing immunologic or nonimmunologic therapies to eliminate the noncycling cancer stem cell, identify more targets for immunotherapies, develop new vaccines that will not be limited by HLA, and develop methods to identify population at very high risk for relapse in order to accelerate clinical development and avoid toxicity in patients not at risk for relapse.
登录
查看更多内容
影响因子：
168.9
作者：
André-Schmutz, I;Le Deist, F;Cavazzana-Calvo, M
通讯作者：
Cavazzana-Calvo, M
影响因子：
15.9
作者：
Berger, Carolina;Jensen, Michael C.;Riddell, Stanley R.
通讯作者：
Riddell, Stanley R.
影响因子：
30.5
作者：
Ackerman, AL;Kyritsis, C;Cresswell, P
通讯作者：
Cresswell, P
影响因子：
56.9
作者：
Arstila, TP;Casrouge, A;Kourilsky, P
通讯作者：
Kourilsky, P
影响因子：
15.3
作者：
Bonifaz, L;Bonnyay, D;Mahnke, K;Rivera, M;Nussenzweig, MC;Steinman, RM
通讯作者：
Steinman, RM